MARKET

GBT

GBT

Global Blood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.62
+0.39
+1.02%
Closed 16:01 05/07 EDT
OPEN
38.69
PREV CLOSE
38.23
HIGH
39.12
LOW
37.66
VOLUME
838.29K
TURNOVER
--
52 WEEK HIGH
81.79
52 WEEK LOW
36.01
MARKET CAP
2.40B
P/E (TTM)
-9.5649
1D
5D
1M
3M
1Y
5Y
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units fo...
GlobeNewswire · 1d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 1d ago
Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug
Benzinga · 2d ago
DJ Global Blood Therapeutics Is Maintained at Hold by Canaccord Genuity
Dow Jones · 2d ago
DJ Global Blood Therapeutics Price Target Cut to $40.00/Share From $45.00 by Canaccord Genuity
Dow Jones · 2d ago
--Goldman Sachs Adjusts Price Target for Global Blood Therapeutics to $80 From $85, Maintains Buy Rating
MT Newswires · 2d ago
--Canaccord Genuity Adjusts Global Blood Therapeutics PT to $40 From $45, Maintains Hold Rating
MT Newswires · 2d ago
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
Zacks.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GBT. Analyze the recent business situations of Global Blood through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GBT stock price target is 80.70 with a high estimate of 138.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 370
Institutional Holdings: 68.18M
% Owned: 109.50%
Shares Outstanding: 62.27M
TypeInstitutionsShares
Increased
85
6.76M
New
56
3.72M
Decreased
62
4.83M
Sold Out
55
5.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
President/Chief Executive Officer/Director
Ted Love
Chief Financial Officer
Jeffrey Farrow
Chief Human Resource Officer
Eric Fink
Chief Scientific Officer
Brian Cathers
Other
Jung Choi
Other
David Johnson
Other
Tricia Suvari
Lead Director/Independent Director
Mark Perry
Director
Deval Patrick
Director
Alexis Thompson
Independent Director
Willie Brown
Independent Director
Scott Morrison
Independent Director
Glenn Pierce
Independent Director
Philip Pizzo
Independent Director
Dawn Svoronos
Independent Director
Wendy Yarno
No Data
About GBT
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.

Webull offers kinds of Global Blood Therapeutics Inc stock information, including NASDAQ:GBT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GBT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GBT stock methods without spending real money on the virtual paper trading platform.